{"preliminary_commentary":{"by_channel":{"x_thread":43,"youtube":13,"podcast":12},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05338970\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"HERTHENA-Lung02","nct_id":"NCT05338970","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=herthena-lung02-nct05338970. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants received patritumab deruxtecan (HER3-DXd) 5.6 milligrams per kilogram (mg/kg), intravenously (IV) on Day 1 of each 21-day cycle (every 3 weeks \\[q3W\\]) until occurrence of unacceptable toxicity, radiographic or clinical disease progression (PD), withdrawal of consent, physician decision, pregnancy, loss to follow-up or death, whichever occurs first; data cut-off (DCO) date: 31 May 2024.","label":"Patritumab deruxtecan","type":"EXPERIMENTAL"},{"description":"Participants received platinum-based chemotherapy; pemetrexed (500 milligrams per square meter \\[mg/m\\^2\\]) plus either cisplatin (75 mg/m\\^2) or carboplatin (target area under the plasma concentration-time curve of 5 \\[AUC5\\] by using the Calvert formula), IV on Day 1 of each cycle up to 4 cycles or until PD, whichever occurs first. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy continued treatment with maintenance pemetrexed with no restriction on the number of cycles; data cut-off (DCO) date: 31 May 2024.","label":"Platinum-based chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Nonsquamous Non-small Cell Lung Cancer","EGFR L858R","EGFR Exon 19 Deletion"],"enrollment":{"count":586,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Patritumab Deruxtecan","otherNames":["HER3-DXd","U3-1402"],"type":"DRUG"},{"name":"Platinum-based chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-27","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-05-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1","timeFrame":"Baseline up to approximately 49 months"}],"references":[{"citation":"Mok T, Janne PA, Nishio M, Novello S, Reck M, Steuer C, Wu YL, Fougeray R, Fan PD, Meng J, Sternberg DW, Esker S, Yu HA. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol. 2024 May;20(15):969-980. doi: 10.2217/fon-2023-0602. Epub 2023 Dec 14.","pmid":"38095056","type":"DERIVED"},{"citation":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.","pmid":"37689979","type":"DERIVED"}],"start_date":{"date":"2022-07-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy","url":"https://clinicaltrials.gov/study/NCT05338970"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/herthena-lung02-nct05338970"}